A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-Resistant Prostatic Cancer
Metastasis

Interventions

DRUG: Docetaxel
DRUG: Ifinatamab Deruxtecan
DRUG: MK-5684
DRUG: Abiraterone
DRUG: Enzalutamide
DRUG: Rescue Medication

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]